Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants that can be used with a range of vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients. In light of the advances made, Science magazine hailed cancer immunotherapy as its 2013 Breakthrough of the Year.
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 748.45M; Volume: 292.25K; AvgVol 3m: 2.82M; Beta: 1.96;
P/E: –; EPS: -1.14; EPS growth quarter/prev quarter: 25.30%;
EPS growth this year: 44.60%; EPS growth past 5 years: -2.30%;
EPS ttm: -1.14;
P/S: 8.31; P/B: ; P/Cashflow: 10.13; P/FCF: ;
Sales: 96.52M; Sales growth quarter/prev quarter: 71.30%; Sales growth past 5 years: 84.70%;
Gross Margin: 99.30%; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -96.50%; ROE – return on equity: 80.00%; LT Debt/Equity: ; Total Debt/Equity: ;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 9.60%; Insider Transactions:-4.13%;
Institutional Ownership: 49.40%; Institutional Transactions: 14.37%;
Data update: 07.10.2020.